1014708

Acella Pharmaceuticals, LLC — FEI 3006691461

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
March 8, 2017
Fiscal Year
2017
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Alpharetta, GA (United States)

Additional Details

Postmarket Adverse Drug Experience (PADE)

Citations

IDCFRDescription
673021 CFR 314.80(b)Failure to develop written procedures
683021 CFR 314.80(c)(2)Interval
891221 CFR 314.81(b)(2)Timely submission